Who Owns Janux Therapeutics Stock?
NASDAQ: JANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 101.38%
- Institutions (% of float)
- 102.39%
- Held by insiders
- 0.99%
- Institutional holders
- 285
- Institutions 99.0%
- Insiders 1.0%
- Public and other 0.0%
Who owns Janux Therapeutics stock?
Institutional investors own about 101.4% of Janux Therapeutics's shares, spread across 285 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.99% of JANX.
The largest institutional holders are RA Capital Management, L.P. (18.30%), Blackrock Inc. (10.03%) and Prosight Management, Lp (6.22%). Together, the top 10 institutions control 59.2% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their JANX positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of JANX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| RA Capital Management, L.P. | 11.19M | 18.30% | 0.0% |
| Blackrock Inc. | 6.13M | 10.03% | +12.9% |
| Prosight Management, Lp | 3.80M | 6.22% | +7.2% |
| State Street Corporation | 3.00M | 4.92% | +21.9% |
| FMR, LLC | 2.41M | 3.95% | -4.8% |
| Federated Hermes, Inc. | 2.35M | 3.85% | +4241.2% |
| Point72 Asset Management, L.P. | 1.99M | 3.26% | +72.5% |
| Vanguard Capital Management LLC | 1.86M | 3.04% | +2.5% |
| TCG Crossover Management, LLC | 1.79M | 2.93% | 0.0% |
| Alyeska Investment Group, L.p. | 1.65M | 2.69% | +2.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of JANX
| Fund | Shares | % Held |
|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.04M | 3.33% |
| Federated Hermes MDT Series-Federated Hermes MDT Small Cap Core Fund | 1.37M | 2.25% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.26M | 2.07% |
| iShares Trust-iShares Russell 2000 ETF | 1.11M | 1.82% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 552.37K | 0.90% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 471.46K | 0.77% |
| iShares Trust-iShares Biotechnology ETF | 426.62K | 0.70% |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | 423.65K | 0.69% |
| iShares Trust-iShares Russell 2000 Value ETF | 401.09K | 0.66% |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 381.00K | 0.62% |
Frequently asked questions
Who is the largest shareholder of Janux Therapeutics?
RA Capital Management, L.P. is the largest institutional shareholder of JANX, owning 18.30% of shares outstanding (11.19M shares) as of its latest 13F filing.
What percentage of Janux Therapeutics is owned by institutions?
Institutions own about 101.4% of JANX shares and 102.4% of the public float.
How much of Janux Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.99% of JANX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.